NASDAQ:IMGN ImmunoGen (IMGN) Stock Price, News & Analysis → Alert: Your Bank is Dying – Act Now or Lose Everything! (From Priority Gold) (Ad) Free IMGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$31.23▼$31.2350-Day Range$31.23▼$31.2352-Week Range$3.61▼$31.25Volume40 shsAverage Volume8.78 million shsMarket Capitalization$8.32 billionP/E RatioN/ADividend YieldN/APrice Target$26.48 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends Get ImmunoGen alerts: Email Address ImmunoGen MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside15.2% Downside$26.48 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth362.50%From $0.08 to $0.37 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector817th out of 903 stocksBiotechnology Industry5th out of 10 stocks 1.1 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunoGen has received no research coverage in the past 90 days.Read more about ImmunoGen's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IMGN. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 69.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.78. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for IMGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.07% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ImmunoGen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow by 362.50% in the coming year, from $0.08 to $0.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 43.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis indicator is great for calling bottoms“It was designed to help boost your chances of finding rock solid trade ideas” It’s called the “Master Indicator” And it’s quite possibly one of the most useful indicators you’ll ever use.If you’d like to join me just follow this link here. About ImmunoGen Stock (NASDAQ:IMGN)ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Read More Ad WealthPressThis indicator is great for calling bottoms“It was designed to help boost your chances of finding rock solid trade ideas” It’s called the “Master Indicator” And it’s quite possibly one of the most useful indicators you’ll ever use.If you’d like to join me just follow this link here. IMGN Stock News HeadlinesApril 25, 2024 | seekingalpha.comPolaris Global Equity Composite Q1 2024 CommentaryApril 25, 2024 | investing.comLazard posts first-quarter profit on deals, assets boostApril 23, 2024 | seekingalpha.com3 Potential Biopharma Buyout TargetsMarch 22, 2024 | marketwatch.comAbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen DealFebruary 21, 2024 | msn.comAbbVie plans to offer senior notes to fund Immunogen, Cerevel dealsFebruary 19, 2024 | ca.finance.yahoo.comCERE Aug 2024 30.000 callFebruary 12, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on ImmunoGen (IMGN)February 12, 2024 | msn.comAbbVie revises Q1 earnings outlook as ImmunoGen deal closesFebruary 9, 2024 | finance.yahoo.comIs ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?February 9, 2024 | seekingalpha.comFinal Countdown: AbbVie's Imminent Closure With ImmunoGen And What It MeansFebruary 9, 2024 | msn.comImmunoGen Set to Merge with AbbVie, Awaiting Final ApprovalFebruary 9, 2024 | finance.yahoo.comImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?February 2, 2024 | finance.yahoo.comImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 2, 2024 | finance.yahoo.comImmunoGen, Inc. (IMGN) Interactive Stock Chart - Yahoo FinanceJanuary 9, 2024 | finance.yahoo.comHow ImmunoGen (IMGN) Stock Stands Out in a Strong IndustryJanuary 4, 2024 | nasdaq.comIMGN Quantitative Stock AnalysisJanuary 4, 2024 | msn.comAll You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong BuyDecember 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLYDecember 22, 2023 | finance.yahoo.comAre Investors Undervaluing ImmunoGen, Inc. (NASDAQ:IMGN) By 38%?December 19, 2023 | morningstar.comImmunogen Inc IMGNDecember 16, 2023 | msn.comImmunogen (IMGN) Price Target Increased by 35.04% to 31.68December 7, 2023 | reuters.comAbbvie to focus on smaller deals after Cerevel and ImmunoGen buyoutDecember 7, 2023 | finance.yahoo.comAbbVie acquiring Cerevel Therapeutics in $8.7B dealDecember 5, 2023 | msn.comImmunoGen bags priority review for full approval of ovarian cancer drugDecember 5, 2023 | markets.businessinsider.comImmunoGen Receives FDA's Priority Review For ELAHERE In Platinum-Resistant Ovarian CancerSee More Headlines Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2023Today6/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Price Target and Rating Average Stock Price Target$26.48 High Stock Price Target$31.26 Low Stock Price Target$16.00 Potential Upside/Downside-15.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio390.38 P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$287.61 million Price / Sales28.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book43.99Miscellaneous Outstanding Shares266,264,000Free Float252,764,000Market Cap$8.32 billion OptionableOptionable Beta1.18 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Mark Joseph Enyedy (Age 60)President, CEO & Director Comp: $1.28MDr. Michael J. Vasconcelles M.D. (Age 61)Ph.D., Chief Medical Officer Comp: $304.62kMs. Lauren A. White M.B.A. (Age 45)Senior VP & Chief Financial Officer Anabel ChanHead of Investor RelationsMr. Daniel S. Char J.D. (Age 62)Senior VP, Chief Legal Officer & Secretary Ms. Courtney O'KonekSenior Director of Corporate Communications & Investor RelationsMs. Audrey BerganSenior VP & Chief HR OfficerDr. Theresa G. Wingrove (Age 66)Senior Vice President of Regulatory Affairs & Quality Comp: $548.21kMs. Isabel KalofonosSenior VP & Chief Commercial OfficerMore ExecutivesKey CompetitorsRhythm PharmaceuticalsNASDAQ:RYTMSupernus PharmaceuticalsNASDAQ:SUPNKiniksa PharmaceuticalsNASDAQ:KNSAArcutis BiotherapeuticsNASDAQ:ARQTOcular TherapeutixNASDAQ:OCULView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 40,200 shares on 5/17/2024Ownership: 0.000%PEAK6 Investments LLCSold 7,500 shares on 5/15/2024Ownership: 0.000%Picton Mahoney Asset ManagementSold 247,700 shares on 5/9/2024Ownership: 0.000%Fifth Lane Capital LPSold 33,600 shares on 5/2/2024Ownership: 0.000%Kapitalo Investimentos LtdaBought 31,437 shares on 3/29/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions IMGN Stock Analysis - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price target for 2024? 12 equities research analysts have issued twelve-month price objectives for ImmunoGen's stock. Their IMGN share price targets range from $16.00 to $31.26. On average, they anticipate the company's stock price to reach $26.48 in the next year. This suggests that the stock has a possible downside of 15.2%. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The biotechnology company had revenue of $83.20 million for the quarter, compared to analyst estimates of $49.15 million. ImmunoGen had a negative net margin of 25.56% and a negative trailing twelve-month return on equity of 22.11%. The firm's revenue for the quarter was up 485.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.24) earnings per share. What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). Who are ImmunoGen's major shareholders? ImmunoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Trading LLC (0.00%), PEAK6 Investments LLC (0.00%), Picton Mahoney Asset Management (0.00%) and Fifth Lane Capital LP (0.00%). Insiders that own company stock include Kristine Peterson, Mark J Enyedy, Renee Lentini, Stacy Ann Coen and Theresa Wingrove. View institutional ownership trends. Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More This page (NASDAQ:IMGN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.